Other languages Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.855 ^USD	-6.09%		-17.49%	-11.06%

Mar. 18	Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index	CI
Mar. 15	Allogene Therapeutics Files $500 Million Mixed Shelf	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Allogene Therapeutics Files $500 Million Mixed Shelf	Mar. 15
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops	Mar. 14
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 14
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments	Feb. 16
Aktien New York: Anleger nach US-Wirtschaftsdaten hin- und hergerissen	Jan. 05
Aktien New York: Trübe Stimmung im Servicesektor wirkt positiv	Jan. 05
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic	Jan. 05
Aktien New York Ausblick: Schwächer erwartet nach Arbeitsmarktbericht	Jan. 05
Allogene to cut 22% of its workforce	Jan. 05
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-Based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	Jan. 04
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of Car T Led by ALPHA3	Jan. 04
Allogene Therapeutics, Inc. Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647	Dec. 09
Allogene Therapeutics Shares Jump After Reporting Preclinical Data on AlloCAR T Product Candidate for Cancer	Nov. 03
Allogene Therapeutics, Inc. Presents Preclinical Data on Next Generation Cloak and Dagger Technologies At the Society for Immunotherapy of Cancer Annual Meeting	Nov. 03
Allogene Therapeutics, Inc. Presents Preclinical Data on Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 At the Society for Immunotherapy of Cancer Annual Meeting	Nov. 03
Allogene Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 02
Allogene Therapeutics, Inc. Appoints Geoffrey Parker as Executive Vice President	23-10-16
Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma Lugano	23-06-15
Allogene Therapeutics Finance Chief Eric Schmidt to Step Down	23-06-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Other languages

Filters